Skip to content

Study · Non-randomized trial · 2011

4 results

Prospects of using pancragen for correction of metabolic disorders in elderly people.

Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA, Bondarenko EV

Bulletin of experimental biology and medicine1 Aug 2011Cited by 4 (Europe PMC)

PMID22448364 (opens in a new tab)DOI10.1007/s10517-011-1354-4 (opens in a new tab)PepBankPUB-22448364
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In older patients with type 2 diabetes, pancragen significantly decreased fasting glucose, while untreated patients showed no carbohydrate-metabolism changes.

    In plain wordsIn older diabetes patients, pancragen lowered fasting glucose, while untreated patients showed no changes.

    Peptide
    Pancragen (KEDW)
    Outcome
    DecreaseFasting glucose
    Study

    n: not reported in source

    Comparator
    No pancragen
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In patients with DM2, pancragen significantly decreased glucose level on an empty stomach and in standard glucose tolerance test and reduced plasma concentrations of insulin and insulin resistance index.
    2 context sentences
    Summary · context
    We examined two groups of older persons: 30 healthy and 33 patients with type 2 diabetes mellitius.
    Summary · context
    In patients receiving no pancragen, no changes in carbohydrate metabolism indices were observed.
  2. 02HumanNon-randomized trialEfficacy outcome

    In older diabetes patients, pancragen significantly decreased glucose during a standard glucose tolerance test, while untreated patients showed no changes.

    In plain wordsIn older diabetes patients, pancragen lowered glucose during a glucose tolerance test, while untreated patients showed no changes.

    Peptide
    Pancragen (KEDW)
    Outcome
    DecreaseGlucose tolerance test glucose
    Study

    n: not reported in source

    Comparator
    No pancragen
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In patients with DM2, pancragen significantly decreased glucose level on an empty stomach and in standard glucose tolerance test and reduced plasma concentrations of insulin and insulin resistance index.
    2 context sentences
    Summary · context
    We examined two groups of older persons: 30 healthy and 33 patients with type 2 diabetes mellitius.
    Summary · context
    In patients receiving no pancragen, no changes in carbohydrate metabolism indices were observed.
  3. 03HumanNon-randomized trialEfficacy outcome

    In older diabetes patients, pancragen reduced plasma insulin, while untreated patients showed no carbohydrate-metabolism changes.

    In plain wordsIn older diabetes patients, pancragen lowered insulin, while untreated patients showed no changes.

    Peptide
    Pancragen (KEDW)
    Outcome
    DecreasePlasma insulin
    Study

    n: not reported in source

    Comparator
    No pancragen
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In patients with DM2, pancragen significantly decreased glucose level on an empty stomach and in standard glucose tolerance test and reduced plasma concentrations of insulin and insulin resistance index.
    2 context sentences
    Summary · context
    We examined two groups of older persons: 30 healthy and 33 patients with type 2 diabetes mellitius.
    Summary · context
    In patients receiving no pancragen, no changes in carbohydrate metabolism indices were observed.
  4. 04HumanNon-randomized trialEfficacy outcome

    In older diabetes patients, pancragen reduced the insulin resistance index, while untreated patients showed no carbohydrate-metabolism changes.

    In plain wordsIn older diabetes patients, pancragen lowered the insulin resistance index, while untreated patients showed no changes.

    Peptide
    Pancragen (KEDW)
    Outcome
    DecreaseInsulin resistance index
    Study

    n: not reported in source

    Comparator
    No pancragen
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In patients with DM2, pancragen significantly decreased glucose level on an empty stomach and in standard glucose tolerance test and reduced plasma concentrations of insulin and insulin resistance index.
    2 context sentences
    Summary · context
    We examined two groups of older persons: 30 healthy and 33 patients with type 2 diabetes mellitius.
    Summary · context
    In patients receiving no pancragen, no changes in carbohydrate metabolism indices were observed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 17:05 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.